Background
Methods
Trial design
Patient enrollment
DAB/IL2 administration
Statistical methods
Results
Baseline characteristics of study population and adverse events
Number | Percent | |
---|---|---|
Sex (Male)
| 40 | 67 |
Ethnic Origin (Caucasian)
| 59 | 98 |
Age (Years)
| 61 (median) | |
Stage
| ||
M1A | 10 | 17 |
M1B | 8 | 13 |
M1C | 42 | 70 |
Common Lesion Sites
| ||
Lung | 28 | 47 |
Liver | 28 | 47 |
Lymph Nodes | 23 | 38 |
Subcutaneous | 16 | 27 |
Bone | 13 | 22 |
Spleen | 3 | 5 |
Adrenal Glands | 3 | 5 |
Chemo- Naïve
| 11 | 18 |
Prior Chemo Exposure
| 49 | 82 |
Previous Systemic Treatments
| ||
0 | 11 | 18 |
1 | 18 | 30 |
2 | 17 | 28 |
3 | 9 | 15 |
4 | 4 | 7 |
5 | 1 | 2 |
Previous Adjuvant Therapy
| ||
Dacarbazine/IL-2 | 16 | 27 |
IFN | 5 | 8 |
Previous Active Therapy
| ||
Biochemotherapy | 26 | 43 |
High Dose IL-2 | 8 | 13 |
Anti-CTLA4 | 7 | 12 |
Temozolomide | 7 | 12 |
Vaccine | 7 | 12 |
Adverse Event | Number | Percent |
---|---|---|
Nausea | 23 | 38 |
Fatigue | 13 | 21 |
Emesis | 10 | 16 |
Rash | 9 | 15 |
Chills | 6 | 10 |
Back Pain | 5 | 8 |
Weight Loss | 4 | 7 |
Weakness | 4 | 7 |
Pruritis | 4 | 7 |
Poor Appetite | 4 | 7 |
Shortness of Breath | 4 | 7 |
Pain At Tumor Site | 3 | 5 |
Insomnia | 3 | 5 |
Lethargy | 3 | 5 |
Rib Pain | 2 | 3 |
Fever | 3 | 5 |
Ascites | 2 | 3 |
Cellulitis | 2 | 3 |
Diarrhea | 2 | 3 |
Pedal Edema | 2 | 3 |
Hypotension | 1 | 2 |
Cough | 1 | 2 |
Whole Body Rash | 1 | 2 |
Neck Pain | 1 | 2 |
Presyncope | 1 | 2 |
Malaise | 1 | 2 |
Fluid Retention | 1 | 2 |
Poor Oral Intake | 1 | 2 |
Head Sweats | 1 | 2 |
Diffuse Body Aches | 1 | 2 |
Erythema | 1 | 2 |
Abdominal Pain | 1 | 2 |
Gait Imbalance | 1 | 2 |
Pleuritis | 1 | 2 |
Jaundice | 1 | 2 |
Constipation | 1 | 2 |
Nipple Irritation | 1 | 2 |
Xerostomia | 1 | 2 |
Chest Thrombosis | 1 | 2 |
Vitiligo | 1 | 2 |
Visual Disturbance | 1 | 2 |
Diplopia | 1 | 2 |
Perioral Numbness | 1 | 2 |
Pruritus in Eyes | 1 | 2 |
Examples of clinical responses to DAB/IL2
Objective clinical response rates based on qualitative radiological assessments
Stage | Age | Prior Systemic Therapy | # Cycles | Response |
---|---|---|---|---|
M1A (7/10) | 59 | None | 4 | PR |
78 | None | 2 | SD | |
83 | None | 2 | MR | |
64 | ADI, BCT, αCTLA4, VAC | 4 | PR | |
60 | AIFN, BCT, TEM | 4 | PR | |
45 | ADI, IFN, VAC | 4 | PR | |
75 | AIFN, BCT | 4 | SD | |
M1B (1/8) | 67 | ADI | 4 | SD |
M1C (14/42) | 78 | None | 2 | PR |
83 | None | 3 | PR | |
82 | None | 3 | PR | |
61 | None | 4 | PR | |
59 | None | 4 | MR | |
47 | BCT, HDIL2, TKI258 | 3 | PR | |
62 |
αCTLA4 | 4 | PR | |
55 | BCT, HDIL2, TKI258 | 4 | MR | |
70 | ADI, BCT | 2 | MR | |
30 | BCT | 4 | MR | |
30 | BCT, HDIL2, αCTLA4, TKI258 | 2 | MR | |
45 | BCT | 4 | MR | |
61 | BCT | 3 | MR | |
58 | ADI, VAC | 4 | MR |